ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
Phase 3
Completed
- Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Interventions
- Biological: Ravulizumab
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03131219
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
Phase 2
Completed
- Conditions
- C3 GlomerulonephritisImmune Complex Mediated Membranoproliferative GlomerulonephritisMembranoproliferative Glomerulonephritis Types I, II, and IIIDense Deposit DiseaseC3 Glomerulopathy
- Interventions
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03124368
- Locations
- 🇳🇱
Clinical Trial Site, Leiden, Netherlands
A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03108274
- Locations
- 🇳🇿
Clinical Trial Site, Auckland, New Zealand
A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)
Phase 1
Terminated
- Conditions
- Warm Autoimmune Hemolytic Anemia
- Interventions
- Drug: ALXN1830
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03075878
- Locations
- 🇯🇴
Alexion Study Site, Amman, Jordan
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
Phase 1
Terminated
- Conditions
- PemphigusPemphigus VulgarisPemphigus Foliaceus
- Interventions
- Drug: ALXN1830
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03075904
- Locations
- 🇺🇸
Alexion Study Site, Philadelphia, Pennsylvania, United States
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Phase 3
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 197
- Registration Number
- NCT03056040
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03053102
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
Study of Samalizumab in Patients With Advanced Cancer
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02987504
Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Phase 3
Completed
- Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Interventions
- Biological: Ravulizumab
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT02949128
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Biological: RavulizumabBiological: Eculizumab
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT02946463
- Locations
- 🇬🇧
Research Site, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath